Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

6.89USD
3:59pm EST
Change (% chg)

$-0.37 (-5.10%)
Prev Close
$7.26
Open
$7.19
Day's High
$7.26
Day's Low
$6.88
Volume
94,222
Avg. Vol
249,801
52-wk High
$22.00
52-wk Low
$6.28

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Says João Siffert Will Not Serve On Board During His Tenure As Interim CEO
Friday, 30 Nov 2018 06:38am EST 

Nov 30 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS INC - JOÃO SIFFERT WILL NOT SERVE ON BOARD OF DIRECTORS DURING HIS TENURE AS INTERIM CHIEF EXECUTIVE OFFICER - SEC FILING.ABEONA THERAPEUTICS - ON NOV 29, FRANK CARSTEN THIEL, CO ENTERED SEPARATION AGREEMENT.ABEONA THERAPEUTICS - SEPARATION AGREEMENT PROVIDING FRANK CARSTEN THIEL WILL NOT OTHERWISE BE ELIGIBLE FOR ANY ANNUAL BONUS OR SEVERANCE AMOUNT.  Full Article

Abeona Therapeutics Announces CEO Transition
Monday, 26 Nov 2018 04:30pm EST 

Nov 26 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS ANNOUNCES CEO TRANSITION.ABEONA THERAPEUTICS INC - ANNOUNCED IMMEDIATE TERMINATION OF ITS CHIEF EXECUTIVE OFFICER, CARSTEN THIEL.ABEONA THERAPEUTICS INC - HAS APPOINTED JOÃO SIFFERT, AS INTERIM CHIEF EXECUTIVE OFFICER.ABEONA THERAPEUTICS INC - TERMINATION OF CEO "DUE TO PERSONAL MISCONDUCT THAT VIOLATED COMPANY'S CODE OF BUSINESS CONDUCT AND ETHICS".ABEONA THERAPEUTICS - THIEL'S TERMINATION FOLLOWS INVESTIGATION BY BOARD, EXTERNAL COUNSEL INTO ALLEGATIONS OF MISCONDUCT TOWARDS COLLEAGUES.ABEONA THERAPEUTICS INC - BOARD HAS FORMED A SEARCH COMMITTEE TO IDENTIFY A PERMANENT SUCCESSOR, WITH ASSISTANCE OF A EXECUTIVE SEARCH FIRM.  Full Article

Abeona Therapeutics Q3 Loss Per Share $0.34
Friday, 9 Nov 2018 04:20pm EST 

Nov 9 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.7 MILLION VERSUS $219,000.Q3 REVENUE VIEW $393,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics Q3 Loss Per Share $0.34
Friday, 9 Nov 2018 04:20pm EST 

Nov 9 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.7 MILLION VERSUS $219,000.Q3 REVENUE VIEW $393,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics May Offer And Sell Common Shares Of Up To $150 Mln Through Jefferies
Friday, 17 Aug 2018 05:27pm EDT 

Aug 17 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS - MAY OFFER AND SELL COMMON SHARES OF UP TO $150 MILLION THROUGH JEFFERIES LLC.  Full Article

Abeona Therapeutics Q2 Loss Per Share $0.25
Thursday, 9 Aug 2018 04:20pm EDT 

Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.25.Q2 REVENUE $819,000 VERSUS $217,000.Q2 REVENUE VIEW $1.1 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2018 WERE $120 MILLION.  Full Article

Abeona Therapeutics Q2 Loss Per Share $0.25
Thursday, 9 Aug 2018 04:20pm EDT 

Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.25.Q2 REVENUE $819,000 VERSUS $217,000.Q2 REVENUE VIEW $1.1 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial
Friday, 18 May 2018 09:25am EDT 

May 18 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING.ABEONA THERAPEUTICS- ABO-102 18-MONTH EFFICACY & SAFETY DATA CONTINUE TO DEMONSTRATE TIME- & DOSE-DEPENDENT REDUCTIONS IN UNDERLYING DISEASE PATHOLOGY.ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN.ABEONA THERAPEUTICS INC - ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED.  Full Article

Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share
Friday, 11 May 2018 08:15am EDT 

May 11 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.18.Q1 REVENUE $2.6 MILLION VERSUS $186,000.Q1 REVENUE VIEW $228,000 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018 WERE $132 MILLION, COMPARED TO $137.8 MILLION AS OF DECEMBER 31, 2017.  Full Article

Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia
Monday, 23 Apr 2018 08:15am EDT 

April 23 (Reuters) - Abeona Therapeutics Inc ::ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA.ABEONA THERAPEUTICS INC - COMPANY CONTINUES TO ENGAGE FDA ON ITS ONGOING PHASE 1/2 TRIAL.ABEONA - FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION TO ABO-102, CO'S GENE THERAPY FOR TREATMENT OF SANFILIPPO SYNDROME TYPE A.  Full Article